Loading...
Loading...
- Alcon AG ALC reported first-quarter FY21 sales of $1.9 billion, an increase of 5% Y/Y on a reported basis and 2% on a constant currency basis, slightly below the consensus of $1.92 billion.
- Core diluted EPS of $0.49 beat the consensus of $0.45, and diluted EPS of $0.17 was a turnaround from a loss of $0.12 a year ago.
- Surgical net sales of $1.1 billion increased 9% Y/Y, or 7% on a constant currency basis, primarily driven by demand for cataract and refractive equipment and other refractive products and continued strength in PanOptix and the launch of Vivity.
- Consumables sales were similar to the previous year's levels due to the continued impact of COVID-19 on surgical procedures.
- Vision Care net sales of $0.8 billion declined 1% Y/Y or 3% on a constant currency basis. Contact lens sales benefited from the recent Precision1 sphere and toric launch but were more than offset by declines in international markets.
- Sales in the prior-year period benefited from higher than normal demand in the U.S. for ocular health products at the beginning of the COVID-19 pandemic.
- Core operating income of $344 million, with a margin of 18.0% up 140 bps, due to an increase in sales partially offset by increased investment in R&D and marketing and sales spend.
- ALC declared its first dividend of CHF 0.10 per share, which is expected to be paid on May 6.
- The company ended the first quarter with a cash of $1.6 billion, and its Free cash flow reached $48 million compared to an outflow of $60 million in the previous year.
- Guidance: It sees FY21 core EPS of $1.85-$1.95 vs. $1.92 estimate, and sales of $7.8 -$8 billion versus an estimate of $7.87 billion.
- Price Action: ALC shares are down 4.58% at $71.12 during the market trading session on the last check Wednesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in